Canaccord Genuity
Canaccord Genuity is the global capital markets division of Canaccord Financial Inc. (CF : TSX | CF. : AIM), offering institutional and corporate clients idea-driven investment banking, research, sales and trading services.
The companies has operations in 24 cities worldwide and the ability to list companies on 10 stock exchanges.
-
Intersect ENT (XENT) PT Raised to $40 at Canaccord Genuity; Sees Improving Commercial Momentum in 2019
-
Intersect ENT (XENT) PT Raised to $46 at Canaccord Genuity
-
Intersect ENT to Present at the Canaccord Genuity Medical Technology & Diagnostics Forum
-
Intersect ENT to Present at the Canaccord Genuity Medical Technology & Diagnostics Forum
-
Intersect ENT to Present at the Wedbush PacGrow Life Sciences and Canaccord Genuity Conferences
-
UPDATE: Cantor Fitzgerald Starts Intersect ENT (XENT) at Buy
-
Intersect ENT Announces Exercise of Underwriters’ Option and the Closing of Its Public Offering
-
Intersect ENT (XENT) Prices Larger 3.58M Common Offering at $25/Share
-
Intersect ENT Announces Upsizing and Pricing of Public Offering
-
Intersect ENT (XENT) Commences 3M Common Stock Offering
-
Intersect ENT Commences Public Offering
-
Intersect ENT Files S-1 Registration Statement for Proposed Public Offering
-
Canaccord Genuity Starts Intersect ENT (XENT) at Buy
-
Intersect ENT to Present at Canaccord Genuity and Piper Jaffray Conferences

